We expect that to happen in 2027 with continued significant growth anticipated in the following years. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. It .
AbbVie Inc. (ABBV) Stock Forecast & Price Prediction For 2023 2024 2025 Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. Shares are consolidating with a buy. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Enjoy your holiday weekend and catch up on our most read stories this week. Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. The median. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. Real-time analyst ratings, insider transactions, earnings data, and more. I wrote this article myself, and it expresses my own opinions. Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally.
Abbvie Stock Forecast 2023, 2024, 2025, 2030 - Stock in US Forecasts shouldnt be used as a substitute for your own research. Projections are based on making fundamental and technical studies of the ABBV stock price performance. But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. I am not receiving compensation for it (other than from Seeking Alpha). The material provided on this website is for information purposes only and should not be understood as an investment advice. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth.
Abbvie Stock Forecast | Is Abbvie a Good Stock to Buy? - Capital Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock.
AbbVie - ABBV Stock Forecast, Price & News - MarketBeat Only you can design whether Abbvie stock is the right investment for you. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ).
On average, analysts rate AbbVie stock as a buy. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.".
AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook This suggests a possible upside of 3.2% from the stock's current price. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Sign in to your free account to enjoy all that MarketBeat has to offer. Investors are already flocking there for a chance at 1,000%+ returns. Having so much debt in a prevailing inflationary environment is also unattractive. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. . The stocks growth marks a significant outperformance over the broader markets. Is this happening to you frequently? If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. I have no business relationship with any company whose stock is mentioned in this article. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Wallet Investor suggested that the price could hit $300.386 in June 2027. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? My No. If you have an ad-blocker enabled you may be blocked from proceeding. All Rights Reserved. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). With a 5-year investment, the revenue is expected to be around +88.28%. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. View the best growth stocks for 2023 here. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. Build a CFD portfolio with your favourite companies. Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. CNN Sans & 2016 Cable News Network. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. AbbVie has a P/B Ratio of 15.97. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. As I have mentioned in previous notes, however, the gains owe more to price hikes than sales volumes, and come 2023 and the LOE, even AbbVie admits the blow to revenues will be substantial. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. The five-year dividend growth rate is just below 18%.
AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. Abbvie stock price has put up an impressive performance in 2022. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. What is Richard A. Gonzalez's approval rating as AbbVie's CEO? Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. To summarize, Humira may be going off-patent, but is more than capable of delivering double-digit billion revenues for another 3-4 years, and even in 2030, it could be amongst the top 20 best-selling drugs worldwide. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. (my tables). I have been maintaining a revenue forecasting table for AbbVie's products which I have amended based on Q2'22 and H1'22 results, and the slightly downgraded guidance issued for 2022 - management now expects adjusted earnings per share ("EPS") of $13.78 - $13.98, representing growth of 17% at the midpoint. During the same quarter in the prior year, the firm posted $3.31 EPS.
AbbVie (ABBV) Stock Forecast & Price Target - TipRanks In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. 16 analysts have issued 12-month price targets for AbbVie's shares. A Warner Bros. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Only 0.08% of the stock of AbbVie is held by insiders. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. On average, they expect the company's stock price to reach $161.12 in the next twelve months. The Abbvie stock forecast for 2025 had the price at $259.018. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated.
AbbVie sees strong 2022 earnings as Botox, Skyrizi power profit beat By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money.
Research Reports & Trade Ideas - Yahoo Finance ABBV Stock Forecast Price Target for 2024 TradingView Retail sales were up but so was inflation which meant more volatility for stocks. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Please. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! The lowest target is $136.35 and the highest is $210. As such I have modelled similar, although I have included an additional revenue stream from new products which I expect to be minor in nature but ultimately contributing an additional $1.5bn to the top line. The total revenue in 2021 was $56.20 billion with a 31% operating margin. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. AbbVie has received a consensus rating of Hold. All rights reserved. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Move your mouse over a quarter or year to see how estimates have changed over time. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. There are currently 9 hold ratings and 7 buy ratings for the stock. You should consider whether you understand how CFDs work and can afford the risks. Skyrizi - which inhibits the activities of IL-23 - a naturally occurring cytokine that is involved in inflammatory and immune responses - and Rinvoq - a member of the janus kinase inhibitor drug class - fit this profile. On average, they predict the company's stock price to reach $161.12 in the next year. One share of ABBV stock can currently be purchased for approximately $156.06. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: The company is focused on research and has a number of collaborations and partnerships to that end. Since then, however, the stock price has fallen 18% to its current price of $142.6. Kateryna Onyshchuk/iStock via Getty Images. Rinvoq's progress has been a little more circumspect, but almost as impressive. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. See what's happening in the market right now with MarketBeat's real-time news feed. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. All rights reserved. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. This suggests a possible upside of 3.8% from the stock's current price. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. This means that . I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. 2022 Cable News Network. Read our dividend analysis for ABBV. I have no business relationship with any company whose stock is mentioned in this article. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. The official website for the company is www.abbvie.com. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. First of all, as shown in the table above I forecast product sales out to 2030. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Zscaler, Inc Plummets, Is It Time To Buy The Dip? . Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. What guidance has AbbVie issued on next quarter's earnings? How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. This would represent an increase of 1.78%. AbbVie's Dividend and Valuation. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Receive regular, detailed analysis focused on biotech and healthcare stocks. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price.
AbbVie Inc. (ABBV) Analyst Ratings, Estimates & Forecasts - Yahoo Finance After 2022 Humira's row is shaded yellow to signify patent expiry. ABBV currently yields 4.1% and has raised its dividend every year since 2013. The eye-disease markets are very large - Regeneron's Eylea is a >$7bn per annum selling drug and AMD markets are >$20bn in size. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise.
AbbVie (ABBV) stock Forecast for 2021 - 2025 - PandaForecast.com Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Data from two Phase 3 induction studies and one maintenance study supported the approval. View ABBV analyst ratings or view top-rated stocks. The ex-dividend date of this dividend is Thursday, April 13th. What other stocks do shareholders of AbbVie own? In February, a Phase 3 induction study saw positive top-line results. The dividend payout ratio is 89.56%. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. I hope to see you there. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. What is a Good Dividend Yield? AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Forecast . According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets.